Author

Julius Chembo

Washington University in St. LouisORCID 0000-0002-5761-3567Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:metabolomics· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Brittany M. BowmaniD· 1 shared Chorlada PaiboonrungruangiD· 1 shared Emily WilkersoniD· 1 shared Gary J. PattiiD· 1 shared Kevin ChoiD· 1 shared Kyle M. LaPakiD· 1 shared Matthew R. MedcalfiD· 1 shared Michael B. MajoriD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Brittany M. BowmanORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintFeb 13, 2025

Pyrimethamine and a potent analogue WCDD115 inhibit NRF2 by suppressing DHFR and one-carbon metabolism

Julius Chembo, Brittany M. Bowman, Kyle M. LaPak…·Michael B. Major

This paper identifies Pyrimethamine and its derivative WCDD115 as potent inhibitors of NRF2 by targeting DHFR and one-carbon metabolism, with WCDD115 showing 22-fold greater efficacy.

4 citations

humanmetabolomics

𝕏 PostBluesky